High Tower Advisors, LLC Affimed N.V. Transaction History

High Tower Advisors, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$0.32 - $0.62 $3,520 - $6,820	11,000 New	11,000 $6,000
Q3 2021 Nov 12, 2021	SELL	$5.54 - $7.51 $55,400 - $75,100	-10,000 Closed	0 $0
Q2 2021 Aug 06, 2021	BUY	$7.78 - $11.4 $77,800 - $114,000	10,000 New	10,000 $85,000
Q1 2021 May 10, 2021	SELL	$5.12 - $8.48 $91,648 - $151,792	-17,900 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$3.16 - $7.03 $20,224 - $44,992	6,400 Added 55.65%	17,900 $104,000
Q3 2020 Nov 13, 2020	SELL	$3.26 - $4.73 $9,780 - $14,190	-3,000 Reduced 20.69%	11,500 $38,000
Q2 2020 Aug 10, 2020	SELL	$1.58 - $4.63 $28,440 - $83,340	-18,000 Reduced 55.38%	14,500 $68,000
Q1 2020 May 21, 2020	BUY	$1.44 - $3.02 $4,320 - $9,060	3,000 Added 10.17%	32,500 $53,000
Q4 2019 Feb 14, 2020	SELL	$2.25 - $3.07 $39,375 - $53,725	-17,500 Reduced 37.23%	29,500 $81,000
Q3 2019 Nov 12, 2019	BUY	$2.67 - $3.65 $13,350 - $18,250	5,000 Added 11.9%	47,000 $138,000
Q2 2019 Aug 13, 2019	BUY	$2.6 - $4.21 $49,400 - $79,990	19,000 Added 82.61%	42,000 $121,000
Q1 2019 May 15, 2019	BUY	$3.05 - $4.34 $9,150 - $13,020	3,000 Added 15.0%	23,000 $95,000
Q4 2018 Feb 14, 2019	BUY	$2.82 - $4.67 $11,280 - $18,680	4,000 Added 25.0%	20,000 $62,000
Q3 2018 Nov 09, 2018	BUY	$1.45 - $6.15 $23,200 - $98,400	16,000 New	16,000 $69,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on High Tower Advisors, LLC with notifications on news.